Human Genome Sciences Rising On Unusual Volume (HGSI)

Human Genome Sciences HGSI is rising on unusual volume during Thursday's trading session. HGSI has surged 4.55% to $25.44. Volume has been heavy, with more than 2.75 million shares already changing hands on the day. Human Genome Sciences (HGS) is a commercially focused biopharmaceutical company. The Company has three products in late-stage clinical development: BENLYSTA for systemic lupus erythematosus (SLE), ZALBIN for chronic hepatitis C, and raxibacumab for inhalation anthrax.